Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios

被引：0
作者：
Katerina S. Konstantinoff
Ajaykumar C. Morani
Thomas A. Hope
Priya R. Bhosale
Isaac R. Francis
Motoyo Yano
Amir Iravani
Nikolaos A. Trikalinos
Malak Itani
机构：
[1] Washington University School of Medicine,Mallinckrodt Institute of Radiology
[2] The University of Texas MD Anderson Cancer Center,Department of Radiology
[3] The University of California,Department of Radiology and Biomedical Imaging
[4] Michigan Medicine,Department of Radiology
[5] Mayo Clinic Hospital,Department of Radiology
[6] University of Washington,Department of Radiology
[7] Washington University School of Medicine,Department of Internal Medicine
来源：
Abdominal Radiology | 2023年 / 48卷
关键词：
Pancreatic neuroendocrine neoplasm; Imaging; CT; MRI; Somatostatin receptor PET;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The clinical and imaging presentation of pancreatic neuroendocrine tumors (PanNETs) is variable and depends on tumor grade, stage, and functional status. This degree of variability combined with a multitude of treatment options and imaging modalities results in complexity when choosing the most appropriate imaging studies across various clinical scenarios. While various guidelines exist in the management and evaluation of PanNETs, there is an overall lack of consensus and detail regarding optimal imaging guidelines and protocols. This manuscript aims to fill gaps where current guidelines may lack specificity regarding the choice of the most appropriate imaging study in the diagnosis, treatment planning, monitoring, and surveillance of PanNETs under various clinical scenarios.
引用
收藏
页码：1843 / 1853
页数：10
相关论文
共 253 条
  • [1] McKenna LR(2014)Update on pancreatic neuroendocrine tumors Gland Surg. 3 258-275
  • [2] Edil BH(2008)One hundred years after ”carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol. 26 3063-3072
  • [3] Yao JC(2007)Plasminogen activator inhibitor-1 in vascular thrombosis Curr Drug Targets. 8 966-1002
  • [4] Hassan M(2011)The epidemiology of gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am. 40 1-18
  • [5] Phan A(2010)Pancreatic endocrine tumors: radiologic-clinicopathologic correlation Radiographics. 30 1445-1464
  • [6] Dagohoy C(2016)ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors Neuroendocrinology. 103 153-171
  • [7] Leary C(2012)Pathology - grading and staging of GEP-NETs Best Pract Res Clin Gastroenterol. 26 705-717
  • [8] Mares JE(2012)Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: multicenter study Cancer Res Treat. 44 157-165
  • [9] Westrick RJ(2008)Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival Ann Oncol. 19 1727-1733
  • [10] Eitzman DT(2018)Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors Journal of nuclear medicine. 59 66-74
12345678910